- Report
- April 2025
- 175 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- April 2025
- 200 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- May 2024
- 138 Pages
Global
From €5915EUR$6,499USD£5,024GBP
- Report
- July 2024
- 161 Pages
Global
From €7236EUR$7,950USD£6,146GBP
- Report
- October 2023
- 175 Pages
Global
From €4096EUR$4,500USD£3,479GBP
Norditropin is a brand of human growth hormone (HGH) used to treat endocrine and metabolic disorders. It is a recombinant DNA-derived HGH, which is identical to the naturally occurring hormone produced in the body. Norditropin is used to treat growth failure in children and adults due to inadequate secretion of endogenous growth hormone, as well as to treat short stature associated with Turner syndrome, Prader-Willi syndrome, and chronic renal insufficiency. It is also used to treat adults with growth hormone deficiency.
Norditropin is available in a variety of dosage forms, including injection pens, cartridges, and vials. It is administered subcutaneously, usually once daily. The most common side effects of Norditropin include injection site reactions, headache, and upper respiratory tract infection.
The market for Norditropin is highly competitive, with several companies offering similar products. Some of the major players in the market include Novo Nordisk, Pfizer, Eli Lilly, Merck, and Sanofi. Show Less Read more